AdvaMed, the Medtech Association, announced on October 28, 2026 in Washington, D.C. that its Digital Health Tech Board of Directors approved Data Access Principles & Best Practices, a voluntary framework for how medical technology companies and health systems handle data. The board signed off on the document on October 19, according to the association’s materials.
The stated goal is plain. AdvaMed wants vendors and hospitals to collaborate on responsible data access, use, and protection, with patient trust, better care, research, innovation, and artificial intelligence all named as the payoffs. The AdvaMed Data Access Principles are not a law, and the association says so by calling them voluntary.
That might look like a story for hospital lawyers, not for readers of a software desk. It is not. Every connected infusion pump, imaging platform, and monitoring app ships code that touches patient data, and engineers decide what gets logged, what gets exported, and what leaves a hospital network. After incidents such as the Icepick leak that exposed more than 40,000 DHS employees, buyers are asking harder questions about who holds data and why. This framework is AdvaMed’s attempt to give both sides a shared script before those questions turn into disputes.
Don't miss new tech stories on Google
Add Tech Insider once in the Google app and our stories appear in your news suggestions.
What AdvaMed Announced on October 28, 2026
The facts that AdvaMed has confirmed are short. The Digital Health Tech Board of Directors approved the framework on October 19, 2026. The association made it public nine days later. The title of the document is Data Access Principles & Best Practices. It is voluntary, and it is written for the working relationship between medtech companies and the health systems that buy and run their products.
The announcement does not name a spokesperson, and the available source text carries no direct quotation from an AdvaMed executive. It also gives no prices, sales figures, adoption targets, or enforcement dates. That absence matters for how readers should treat the news. This is a statement of expected practice from a trade association, not a regulatory action and not a market-moving financial event.
What the document does offer is structure. It sets out four principles and applies them to a specific scenario, which the association describes as introducing and supporting a medtech product or service in a U.S. health system. That scenario runs from evaluation and implementation through operation and optimization. In other words, the framework follows a product across its whole life inside a hospital instead of treating data sharing as a one-time contract clause.
The Four Principles at a Glance
AdvaMed organizes the framework around four named principles. The table below lists them exactly as AdvaMed titles them and adds a plain-language reading of what each one asks of the parties. The readings are this desk’s interpretation of the titles and of AdvaMed’s stated purpose, not additional text from the framework.
| Principle (AdvaMed title) | Plain-language reading | Who feels it first |
|---|---|---|
| Transparency and Clear Expectations | Both sides state up front what data moves and what each party expects | Contracting and procurement teams |
| Responsible Data Stewardship | Protect data across its lifecycle, from collection to disposal | Security and privacy officers |
| De-Identification as a Foundation for Innovation | Use de-identified data as the default route to research and product work | Data science and analytics teams |
| Use AI and Advanced Analytics Responsibly | Apply AI under oversight and with clear accountability | Product managers and ML engineers |
| Overall status | Voluntary best practices, not a binding rule | Every signatory to a vendor-hospital deal |
The order is telling. Expectations come first, stewardship second, de-identification third, and AI last. That sequence suggests AdvaMed sees trust and basic hygiene as the base layer, with AI as something that can only be added once the base is sound.
Why the Framework Targets Health-System Deployments
The framework’s primary use case is the arrival of a new medtech product inside a U.S. health system. That is where data disagreements tend to start. A hospital buys a device or a software service, the vendor wants usage and performance data to improve it, and the hospital wants to protect patients and limit liability. Without shared language, each deal becomes a custom negotiation.
By walking through evaluation, implementation, operation, and optimization, AdvaMed acknowledges that data needs change at each stage. During evaluation, a hospital may share little. During operation, the product may stream device telemetry around the clock. During optimization, the vendor may want to study that history to tune algorithms. A framework that names those phases lets both parties agree early on which data flows are expected at which point.
For engineers, the phase model maps neatly onto familiar work. Proof-of-concept builds, production rollouts, and ongoing model tuning each carry different data access requirements. Teams that document those requirements per phase will find the AdvaMed language easy to adopt.
Which Data Types Fall Under the AdvaMed Data Access Principles
The scope is broad. AdvaMed says the framework covers protected health information, consumer health data, several forms of altered patient data, and non-personal data from devices and operations. The breadth is deliberate. A vendor rarely handles only one kind of data, and a hospital cannot safely reason about one category while ignoring the neighbors.
| Data category (per AdvaMed) | Why it matters to a medtech deployment |
|---|---|
| Protected health information | Directly identifies patients and sits under existing privacy law |
| Consumer health data | Often flows from patient-facing apps and wearables outside a clinical setting |
| De-identified data | The category AdvaMed treats as a foundation for innovation |
| Pseudonymized data | Replaces direct identifiers but may still carry re-identification risk |
| Coded data | Uses a key or code that can link records back under controlled conditions |
| Aggregated data | Combines records into summaries for analysis and benchmarking |
| Device, operational, and other non-personal data | Logs, performance metrics, and utilization signals that are not about a person |
The inclusion of pseudonymized and coded data deserves attention. Those labels sit between fully identified and fully de-identified, and they are where many real-world data deals live. By naming them, AdvaMed signals that the gray zone needs explicit treatment instead of a single “anonymized” label that may overpromise.
Principle One: Transparency and Clear Expectations
The first principle, “Transparency and Clear Expectations,” asks both parties to be open about what they plan to do with data. In practice that means contracts, documentation, and privacy notices that say which data is involved, who plays which role, and what uses are allowed. The idea is not exotic. Many hospitals already require this in vendor reviews. What AdvaMed adds is an industry-wide statement that vendors should expect to provide it.
The business logic is easy to follow. Vague data terms slow procurement, and slow procurement delays products reaching clinicians. If a vendor can point to a recognized industry framework when answering a data question, the hospital’s legal team spends less time on first principles. Both sides save weeks.
Principle Two: Responsible Data Stewardship
“Responsible Data Stewardship” is the security and governance principle. It covers safeguards that fit the sensitivity of the data, care about how long data is kept, and internal oversight such as training and accountability. The AdvaMed announcement frames stewardship as a shared duty, not something one party can hand to the other.
Developers know this territory well. Secrets management, least-privilege access, and logging discipline are the day-to-day mechanics of stewardship. Teams that have already audited how their tools handle credentials, as in this walkthrough of keeping secrets away from AI editors, will recognize the habit. The medtech version simply carries higher stakes because the data describes people’s health.
Principle Three: De-Identification as a Foundation for Innovation
The third principle is the most strategic. By calling de-identification “a foundation for innovation,” AdvaMed positions properly stripped data as the safe road to research and product improvement. If a vendor can learn from de-identified device data without ever touching a patient’s name, many privacy conflicts shrink.
The catch is that de-identification is not a switch. Rich datasets, especially those combining device signals with dates and locations, can sometimes be linked back to individuals. A credible program tests its own methods and revisits them as new data sources appear. AdvaMed’s choice to list pseudonymized and coded data in scope suggests it understands that nuance, though the announcement text available to this desk does not spell out technical standards.
Principle Four: Use AI and Advanced Analytics Responsibly
The fourth principle, “Use AI and Advanced Analytics Responsibly,” ties the framework to the technology that is driving most data demand. Medtech firms want large, varied datasets to train and validate models. Health systems want those models to improve care without exposing patients or creating new risks. The principle sets responsible use as the bridge between those goals.
Evaluation is the hard part. A hospital that deploys an AI-enabled product needs a way to check that it performs as claimed on its own patients. Engineers who build evaluation harnesses for language models will see the parallel in this guide to calibrating an LLM judge in 13 steps, where agreement with human reviewers is measured instead of assumed. Clinical settings will need the same discipline, with higher consequences.
The policy climate around AI is also moving unevenly. TechRadar reported that Australia’s government wants to ban AI chatbots that create emotional intimacy, a plan critics have called an Orwellian system of censorship. That is a different sector and a different jurisdiction, but it shows how quickly governments are willing to draw hard lines around AI. A voluntary framework like AdvaMed’s is partly a bet that industry can set sensible norms before someone else writes harder ones.
What It Means for Software Engineers and Product Teams
The audience for this story on a software desk is the engineer who builds or integrates medtech systems. Voluntary does not mean ignorable. Hospital buyers often turn industry frameworks into checklist items in security questionnaires. A team that cannot answer data-access questions in the vocabulary of the AdvaMed Data Access Principles may find deals moving slower than those of competitors who can.
Practical steps for engineering teams
- Map every data flow in the product and label it with one of the framework’s data categories.
- Document which flows are needed at evaluation, implementation, operation, and optimization.
- Separate identifiable data stores from de-identified and non-personal telemetry.
- Record who decides how AI features use customer data, and how that decision is reviewed.
- Prepare plain-language answers for hospital privacy and security reviews.
Tooling and visibility
Transparency is easier to claim than to prove. Teams that inspect what their own tooling sends over the network, as in this look at telemetry and privacy mode in Cursor and VS Code, already practice the kind of verification that a hospital buyer may ask for. A software bill of materials is another useful artifact, and this comparison of SBOM tools shows what generating one involves.
Voluntary, Not Binding: What the Framework Cannot Do
AdvaMed describes the framework as voluntary, and nothing in the announcement as described suggests it creates a new regulation or an approval pathway. It cannot compel a hospital to share data, force a vendor to sign on, or override privacy law. Those limits are important because the headline language about responsible access can sound stronger than the document’s legal weight.
Critics of trade-association frameworks often make the same point. Voluntary standards can lift the floor for good actors while leaving bad ones untouched. Without audits or a reporting mechanism, adoption is hard to verify. The available announcement does not describe an enforcement or certification process, so readers should not assume one exists.
Still, soft law has real influence. Contracts borrow its language, procurement teams cite it, and regulators sometimes point to industry norms when they decide what counts as reasonable practice. The framework may not bind anyone today, but it could shape what counts as normal in the next round of vendor agreements.
Historical Context: Why Data Access Became a Medtech Flashpoint
Health data rules in the United States grew up around paper records and early electronic systems. The privacy law that most people know, HIPAA, set the baseline long before connected devices streamed continuous readings to cloud analytics platforms. Its de-identification concepts remain central, but the data ecosystem around them has changed enormously.
Public attitudes have also shifted toward wanting more access, not less. A Pew Charitable Trusts brief published in 2021 found broad support for sharing health information. It is older than the 2025 and 2026 developments driving this story, so treat it as background for attitudes, not as a measure of today’s market.
The arrival of machine learning raised the stakes. Models improve with data, which makes health-system datasets valuable to vendors. At the same time, a string of breaches across industries has made hospital boards more cautious. The AdvaMed framework tries to reconcile those pressures with a middle position: share more, but under clearer rules.
Industry Data and Citations on Health Data Sharing
AdvaMed’s announcement carries no on-record quote and no sales figures, so outside research is the best available way to frame the problem. The statements below come from published research and are reproduced word for word. They are not comments on the AdvaMed framework, and neither organization has weighed in on it as far as this desk can confirm. The source links for both were not live-verified by the desk, so the citations name the publisher and title instead.
- The Pew Charitable Trusts, in its 2021 brief “Most Americans Want to Share and Access More Digital Health Data,” reported: “Eighty-one percent of U.S. adults support increased access to health information for patients and providers.”
- The same Pew brief found: “Only 36% of respondents reported that all of their health care providers’ electronic health records allowed them to access their own records electronically.”
- Pew also reported: “Eighty-one percent of respondents said that different providers should be able to share health data about patients they have in common.”
- McKinsey & Company, in its 2025 piece “Making digital healthcare systems interoperable,” wrote: “In 2023, 57% of countries participating in the Global Digital Health Monitor were building or beginning to implement high-level national digital health architectural frameworks.”
- McKinsey added: “As of 2023, only 18% of countries broadly adhered to established data standards that were routinely updated.”
Read together, the figures sketch a gap between demand and delivery. People want data to move to the right places, yet adherence to routinely updated standards is thin. A voluntary framework cannot close that gap alone, but it can give one industry segment a common reference.
Competitive Comparison: Voluntary Frameworks Versus Other Governance Tools
The AdvaMed framework is one governance tool among several. Hospitals and vendors already rely on statutes, state laws, and negotiated contracts. The table compares those approaches in general terms. It does not rank them, since the right mix depends on the deal.
| Approach | Binding? | Main strength | Main weakness |
|---|---|---|---|
| AdvaMed Data Access Principles & Best Practices | No, voluntary | Shared vocabulary across vendors and hospitals | No stated enforcement or certification |
| Federal privacy law such as HIPAA | Yes, for covered parties | Clear legal baseline for protected health information | Predates modern AI and connected-device data flows |
| State privacy laws | Yes, within each state | Can reach consumer health data outside clinical settings | Patchwork of differing requirements |
| Negotiated vendor contracts | Yes, between the parties | Tailored to the specific product and risk | Slow to negotiate and inconsistent across deals |
| Internal AI governance programs | Only by company policy | Fast to adapt to new models | Hard for outsiders to verify |
The comparison shows where AdvaMed’s work fits. It does not replace law or contracts. It tries to make contracts faster and more consistent by supplying agreed language, and it nudges both sides toward practices that statutes alone may not describe.
Market Impact: Who Gains and Who Pays
No financial figures accompany the announcement, so any market impact is indirect. Larger medtech vendors with established privacy teams can adopt the framework with modest effort, and they may gain a selling point in procurement. Smaller firms and startups face a steeper climb, since documentation, governance, and de-identification testing all take staff time.
Health systems stand to gain clarity. If most vendors speak the same language about data, security reviews get shorter and comparisons get easier. The cost lands on hospitals that want to enforce the principles, because they will still need people to check what vendors actually do.
The broader AI conversation adds pressure. Debates over whether to require risk disclosures from frontier AI developers, such as the one covered in this piece on Anthropic’s support for court blocks and six-month risk reports, show that regulators and companies are already negotiating what responsible AI means. Medtech sits downstream of that debate, and its data frameworks will likely borrow from it.
Five Predictions for the Framework
These predictions are this desk’s analysis. They are not statements from AdvaMed, and none is confirmed.
- Procurement language will absorb it. Expect hospital security questionnaires and vendor data addenda to start echoing the four principle names within the next year.
- De-identification testing becomes a selling point. Vendors that can show they regularly check re-identification risk will use it to stand out.
- AI disclosure expectations will tighten. Buyers will ask which features use customer data for model training and who approves that use.
- Other trade groups will publish parallel guidance. Adjacent sectors that share data with health systems have reasons to follow.
- Regulators may cite it as evidence of industry norms. Even without binding force, the framework could inform what officials consider reasonable practice.
The takeaway: the most likely near-term effect is quieter than a headline suggests. Contracts will change first, then audits, then, if adoption is wide, the way regulators describe good behavior.
What Remains Unknown
Several questions are open as of October 29, 2026. The available material does not say how many companies or health systems will adopt the framework, whether AdvaMed plans to track adoption, or whether technical standards for de-identification will follow. It also does not identify a named spokesperson or give a timeline for updates.
Readers who build or buy medtech products should watch for three signals. The first is whether large health systems reference the framework in public procurement guidance. The second is whether AdvaMed publishes companion tools such as sample contract language. The third is whether the framework gets cited in any regulatory or legislative discussion. Until then, treat it as a guide to expected behavior, not as proof of compliance. For more developer-focused coverage, see the software section.
FAQ: AdvaMed Data Access Principles
What did AdvaMed announce on October 28, 2026?
AdvaMed announced that its Digital Health Tech Board of Directors approved Data Access Principles & Best Practices, a voluntary framework for responsible data access, use, and protection between medical technology companies and health systems.
When did the board approve the framework?
The framework was approved on October 19, 2026. AdvaMed made the announcement on October 28, 2026.
Is the framework legally binding?
No. AdvaMed describes it as voluntary. It does not replace HIPAA, state privacy laws, or contract terms, and the available announcement describes no enforcement mechanism.
What are the four principles?
They are “Transparency and Clear Expectations,” “Responsible Data Stewardship,” “De-Identification as a Foundation for Innovation,” and “Use AI and Advanced Analytics Responsibly.”
What kinds of data does it cover?
Protected health information, consumer health data, de-identified, pseudonymized, coded, and aggregated data, and device, operational, and other non-personal data.
Does the framework create an FDA approval pathway?
Nothing in the announcement as described says so. It reads as voluntary guidance on data practices for introducing technology into health systems, not as a regulatory submission route.
Why should software developers care?
Developers decide what data products collect, log, and transmit. Hospital buyers may use the framework’s language in security reviews, so teams that can map their data flows to it will likely move through procurement more smoothly.
